Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666819 | 0.79 | EPHX2 (0.41) | EPHX2NPSR1KDM4EPOLBEPHX1 | |
| Hydrochloric Acid SCHEMBL1458776 | 0.77 | EPHX2 (0.40) | EPHX2NPSR1KDM4EPOLBEPHX1 | |
| SCHEMBL1675868 | 0.77 | EPHX2 (0.40) | EPHX2NPSR1KDM4EPOLBEPHX1 | |
| SCHEMBL1560290 | 0.77 | EPHX2 (0.40) | EPHX2NPSR1KDM4EPOLBALDH1A1 | |
| SCHEMBL3546760 | 0.77 | KDM4E (0.36) | EPHX2KDM4EPOLBRECQLEPHX1 | |
| SCHEMBL13611600 | 0.72 | KDM4E (0.44) | NPSR1KDM4EPOLBALDH1A1THRB | |
| SCHEMBL1675833 | 0.72 | KDM4E (0.44) | EPHX2NPSR1KDM4EPOLBALDH1A1 | |
| SCHEMBL19690609 | 0.72 | NAAA (0.46) | EPHX2NPSR1KDM4ERECQLEPHX1 | |
| SCHEMBL2477744 | 0.72 | CYP4F2 (0.39) | NPSR1KDM4EPOLBRECQLEPHX1 | |
| SCHEMBL1203989 | 0.71 | POLB (0.46) | EPHX2KDM4EPOLBRECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| CN-101511836-A | Fused pyrimido compounds | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | EPHX2 1438/4885NPSR1 876/4885KDM4E 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.